UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Apple Turns 50: From Garage Startup to AI Crossroads 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Britain Courts Anthropic Amid US Defense Department Dispute 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
GAITHERSBURG, Md., Sept. 08, 2016 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will participate in the World Anti-Microbial Resistance Congress being held September 8-9 in Washington, D.C. OpGen CEO Evan Jones will lead a presentation titled “Harnessing the power of informatics and genomic analysis to provide complete MDRO solutions” on Thursday, September 8 at 3:05 p.m. ET.
OpGen will also host a roundtable discussion called “Antibiotic resistant bacteria in our Integrated Healthcare Network: are new diagnostic tests needed?” on Friday, September 9 from 1:40 p.m. to 2:20 p.m. ET. The roundtable will feature Bert Lopansri, M.D., Associate Professor of Medicine, University of Utah; Chief of Infectious Diseases, Intermountain Healthcare; and Medical Director, Urban Central Region Microbiology Lab, Division of Infectious Diseases and Epidemiology.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.
OpGen Michael Farmer Director, Marketing (240) 813-1284 [email protected] [email protected] Investor Relations LHA Kim Sutton Golodetz (212) 838-3777 [email protected] or Bruce Voss (310) 691-7100 [email protected] OpGen Media MacDougall Biomedical Communications Cammy Duong 781-235-3060 [email protected]
